Left Atrial Appendage Closure
Where Do We Stand Now?

J. Mauricio Sánchez, MD1* and David R. Holmes, Jr., MD2

1 Department of Cardiac Electrophysiology, The Heart Health Center, Mercy Clinic, St. Louis, Missouri, USA
2 Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA

Abstract
Atrial fibrillation is the most common arrhythmia with significant morbidity and mortality. The most feared complication of atrial fibrillation remains stroke. While anticoagulation remains the cornerstone of stroke prevention in patients with atrial fibrillation, patients continue to be under treated due to misinformation, intolerance, as well as relative and absolute contraindications. The left atrial appendage has been implicated in thrombus formation in patients with atrial fibrillation. Left atrial appendage closure has been devised as an alternative strategy for decreasing stroke risk in patients with atrial fibrillation. Percutaneous left atrial appendage closure is currently being developed as a possible alternative to anticoagulation in patients at high risk for stroke especially among patients with relative or absolute contraindications to long-term anticoagulation. The PROTECT AF trials provides the first randomized, controlled trial data demonstrating proof of concept of left atrial appendage closure with the WATCHMAN device. Further data are explored in this review. Limited data are available with other devices. However, several devices are promising entries into the realm of left atrial appendage closure offering options to an under treated patient population.

Key Words
Atrial Fibrillation • Left atrial appendage • Left atrial appendage closure • Stroke • Thromboembolism • Bleeding

Introduction
Atrial fibrillation (AF) is the most common arrhythmia, with an overall incidence of 0.4% to 1% in the general population [1-3]. The prevalence of AF increases with age. Given an aging population, the number of patients with AF is likely to increase in the near future. The estimated prevalence in 2010 ranged between 2.1 million and 6.1 million. By 2050, this is projected to increase to between 5.6 and 12 million patients [4], which will present significant challenges for health care delivery. AF results in chaotic atrial contraction and subsequent loss atrial transport function, which impairs left ventricular filling and promotes stasis. The resultant symptoms can range from absent to severe. AF is associated with significant increase in morbidity including congestive heart failure [5], dementia [6], and significant increase in mortality. The most feared complication of AF is stroke from thromboembolism. Patients with AF are at a five times higher risk of stroke [7]. This risk increases with age [8]. Strokes in AF patients are often more severe than in non-AF related strokes [9].

Anticoagulation with vitamin K antagonists has been the cornerstone of stroke prevention in AF patients at high risk for embolic stroke. Vitamin K antagonists have been shown to decrease incidence of thromboembolic stroke in these patients as well as
decreasing the associated mortality from stroke [10]. In clinical practice however, patients who are warfarin eligible are often not treated [11]. In addition, approximately a quarter of patients who initiate therapy will discontinue its use at 1 year [12]. Novel oral anticoagulants (NOAC) have been shown to be non-inferior or superior compared to warfarin but also have discontinuation rates of between 17–25% at 2 years [13-15]. Complications from anticoagulation, including bleeding, intolerance, and falls, present challenges to traditional therapy and NOACs alike.

The left atrial appendage (LAA) is known play a significant role in thrombus formation and stroke in AF, with approximately 90% of thrombi located in the LAA in patients with nonvalvular AF based on echocardiographic and autopsy data [16]. Percutaneous LAA closure has emerged as an alternative strategy for reducing risk of thromboembolic stroke in patients with nonvalvular AF. Understanding the history of LAA closure and the emergence of current percutaneous technologies is imperative to the understanding of the developing field and future indications.

**The Left Atrial Appendage**

The LAA is a complex structure that is a remnant of the embryological left atrium. This pouch-like projection has a variety of morphologic appearances and anatomy with variable size, length, width, and number of lobes. In the setting of AF, poor atrial transport function results in stasis within the LAA. This can be documented by low Doppler inflow velocities on tranesophageal echocardiography (TEE) and by spontaneous echo contrast, which are both associated with increased risk of stroke [17]. The walls can have a significant amount of trabeculations which may predispose to stroke [18]. Four main morphologies have been characterized based on appearance including: chicken wing, cactus, windsock, and cauliflower. Non-chicken wing morphologies are significantly more likely to be associated with a thromboembolic event [19] even after controlling for traditional risk factors (CHADS₂ score.) Other factors such as endothelial dysfunction, inflammation, platelet activation, and hypercoagulable state have also been implicated in having a role the increased risk of thromboembolism [20, 21]. Assessment of stroke risk in AF remains of paramount importance. Utilization of the CHADS₂ score previously and now CHA₂DS₂-VASc score [22] is recommended to determine patient risk per year of stroke and subsequent need for possible anticoagulation (Table 1).

Oral anticoagulation utilizes a systemic approach to decrease thrombus formation and subsequent thromboembolism. In contrast, LAA closure provides a local therapy to achieve a similar result. LAA closure is especially appealing in patients intolerant or with contraindications to systemic anticoagulation.

**Table 1: CHADS₂ and CHA₂DS₂-VASc for ischemic stroke**

<table>
<thead>
<tr>
<th>CHADS₂</th>
<th>Risk Factor</th>
<th>Points</th>
<th>CHA₂DS₂-VASc</th>
<th>Risk Factor</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>Congestive heart failure</td>
<td>1</td>
<td>C</td>
<td>Congestive heart failure</td>
<td>1</td>
</tr>
<tr>
<td>H</td>
<td>Hypertension</td>
<td>1</td>
<td>H</td>
<td>Hypertension</td>
<td>1</td>
</tr>
<tr>
<td>A</td>
<td>Age 75 years</td>
<td>1</td>
<td>A₂</td>
<td>Age 75 years</td>
<td>2</td>
</tr>
<tr>
<td>D</td>
<td>Diabetes mellitus</td>
<td>1</td>
<td>D</td>
<td>Diabetes mellitus</td>
<td>1</td>
</tr>
<tr>
<td>S₂</td>
<td>Previous stroke or TIA</td>
<td>2</td>
<td>S₂</td>
<td>Previous stroke or TIA</td>
<td>2</td>
</tr>
<tr>
<td>V</td>
<td>Vascular disease</td>
<td></td>
<td>V</td>
<td>Vascular disease</td>
<td>1</td>
</tr>
<tr>
<td>A</td>
<td>Age 65–74 years</td>
<td>1</td>
<td>A</td>
<td>Age 65–74 years</td>
<td>1</td>
</tr>
<tr>
<td>Sc</td>
<td>Sex (female gender)</td>
<td></td>
<td>Sc</td>
<td>Sex (female gender)</td>
<td>1</td>
</tr>
</tbody>
</table>

Maximum score 6 9
Surgical Closure

Surgical closure of the LAA has been performed for many years with mixed results. The first reported cases of LAA exclusion in the surgical literature was in 1949, in two patients with recurrent arterial emboli [23]. Since that time, surgical ligation has fallen in and out of favor. TEE assessment has shown surgical techniques to have a high occurrence of unsuccessful closure. Success is dependent on the surgical technique utilized with excision providing the best results [24]. Currently, LAA excision is performed usually as an additional procedure with cardiac surgery or as part of a surgical MAZE procedure. Thoracoscopic LAA excision is mainly performed with thoracoscopic surgical pulmonary vein isolation [25], though stand-alone procedures have been reported [26, 27]. There has been a lack of large, randomized, controlled trials with evaluation of long-term stroke risk after surgical LAA closure. Currently, the Left Atrial appendage Occlusion Study (LAAOS III) is being conducted to evaluate LAA occlusion during on-pump cardiac surgical procedures. It is a large-scale randomized controlled trial with an enrollment goal of 4,700 patients with AF. The end-point will be first occurrence of stroke or systemic arterial embolism over a mean follow up of 4 years.

Surgical clip devices have been developed in order to more predictably close the LAA during cardiac surgical procedures. The AtriClip system (AtriCure-USA, West Chester, Ohio, USA) and the Tigerpaw system (Maquet, Rastatt, Germany) are available in the United States [28, 29]. Advantages of use include utilization with live TEE guidance to evaluate position of the clip prior to final closure. While observational studies have demonstrated safety and feasibility of clip based LAA closure, there are no randomized, controlled trial data demonstrating efficacy with regard to stroke prevention. These devices are usually utilized in patients undergoing cardiac surgery, though stand-alone thoracoscopic implantation has been reported with the AtriClip [30]. Further data should help further delineate the effect on clinical outcome of surgical closure with these novel devices.

Transcatheter Closure

Percutaneous transcatheter approaches have been developed to close the LAA. The inherently less-invasive nature compared to surgical techniques has resulted in significant enthusiasm for transcatheter LAA closure as possible alternative to anticoagulation in patients with nonvalvular AF at high risk for stroke especially among patients with absolute or relative contraindications to long-term anticoagulation. A variety of devices and techniques have been developed with individual development histories and studies which dictate individual efficacy and safety outcomes. Below we discuss, the most frequently studied devices.

PLAATO

The PLAATO device was the first transcatheter LAA occlusion system developed and implanted in humans [31]. The device was a self-expanding nitinol cage covered with an occlusive expanded polytetrafluoroethylene membrane. It was delivered through a trans-septal access into the left atrium via femoral vein. Initial studies demonstrated that transcatheter closure of the LAA with the PLAATO device was feasible and safe in a nonrandomized study of patients at high risk for thromboembolism who were not able to receive warfarin therapy. When compared to expected event rates based on CHADS 2 score, the PLAATO device decrease events by 42–65% [32, 33]. The PLAAITO system was withdrawn from the market in 2006 due to commercial reasons.

Amplatzer Cardiac Plug

The Amplatzer cardiac plug (St. Jude Medical, Minneapolis, Minnesota, USA) known as ACP device was developed specifically for LAA closure. The ACP device is a self-expanding nitinol mesh covered with an occlusive expanded polytetrafluoroethylene membrane. It was delivered through a trans-septal access into the left atrium via femoral vein. Initial studies demonstrated that transcatheter closure of the LAA with the PLAAITO device was feasible and safe in a nonrandomized study of patients at high risk for thromboembolism who were not able to receive warfarin therapy. When compared to expected event rates based on CHADS 2 score, the PLAAITO device decrease events by 42–65% [32, 33]. The PLAAITO system was withdrawn from the market in 2006 due to commercial reasons.
in likely anticipation of still pending FDA approval of the WATCHMAN device [41].

**WATCHMAN**

The WATCHMAN device (Boston Scientific, Natick, Massachusetts, USA) is the most studied LAA closure device currently in use. It consists of a self-expanding nitinol frame with porous polyethylene terephthalate membrane on the face of the device (Figure 2). The device is delivered through the femoral vein into the left atrium via transseptal access. A 14 French access sheath is carefully maneuvered into the LAA body. The device is loaded into the distal sheath and unsheathed with removal of the access sheath while maintaining distal position of the WATCHMAN device within the LAA. The device is secured in position with fixation barbs present along the sides of the device which engage the endocardium.

This device has CE mark approval. It is the first and only LAA closure device to receive FDA approved in the United States. It was evaluated in a large, randomized, controlled trial in patients with nonvalvular AF who were eligible for warfarin therapy and high risk for thromboembolism. The WATCHMAN Left Atrial Appendage system for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) enrolled 707 patients who were candidates for long-term anticoagulation and had nonvalvular AF [42]. The PROTECT AF study was a multicenter non-inferiority trial that randomized patients in a 2:1 fashion to either LAA occlusion with the WATCHMAN device or to warfarin therapy. Patients 18 years old or older with nonvalvular AF were eligible for enrollment with a CHADS 2 score greater than or equal to 1 (i.e., at least one of the following: congestive heart failure, hypertension, age greater than 75 years old, diabetes mellitus, previous stroke or transient ischemic attack [43]). Exclusion criteria for the trial included contraindication to aspirin or warfarin, comorbidities other than AF that required chronic warfarin use, LAA thrombus, patent foramen ovale with atrial septal aneurysm and a right-to-left shunt, mobile atheroma, and symptomatic carotid disease. Patients randomized to the device arm were placed on warfarin and aspirin for 45 days postimplantation. Device arm patients then underwent repeat TEE at 45 days of follow up. War-
warfarin, aspirin (81–325 mg) was continued with the addition of plavix (75 mg) until the 6-month follow up. At this point, plavix was discontinued. Aspirin was discontinued in those patients who either had complete closure of the LAA or a small peridevice leak (jet < 5 mm in width). After discontinuation of

**Figure 2.** Panel A. WATCHMAN device. The WATCHMAN device consists of a self-expanding nitinol frame with fixation barbs. There is a porous polyethylene terephthalate membrane on the face of the device which endothelializes over time occluding the ostium of the appendage (image courtesy of Boston Scientific, Inc.). Panel B. Left atrial appendage (LAA) with pigtail catheter in place. A pigtail catheter is utilized to cannulate the LAA in an atraumatic fashion. Angiography of the LAA is performed to gain an understanding of the anatomy. The WATCHMAN 14 French sheath is placed over the pigtail into the LAA. Panel C. LAA with WATCHMAN sheath. The pigtail catheter is removed and the WATCHMAN 14 French access sheath is carefully maneuvered distally into the LAA. Marker bands which are visible under fluoroscopy allow for determination of where the device will land when access sheath is removed and device unsheathed. Panel D. LAA with WATCHMAN deployed. The device is loaded into the distal sheath and unsheathed with removal of the access sheath while maintaining distal position of the WATCHMAN device within the LAA. The device is secured in position with fixation barbs present along the sides of the device which engage the endocardium.
The PROTECT AF study demonstrated that the WATCHMAN device could be successfully implanted. It was successfully implanted in 88% (408/463) of patients randomized to the WATCHMAN group and in 91% (408/449) of patients in whom implant was attempted. At the 45-day TEE, 86% (349/408) of patients were able to discontinue warfarin. At the 6-month TEE, 92% (355/408) of patients were able to discontinue warfarin. While long-term follow up of PROTECT AF has demonstrated sustained efficacy and confirmed long-term safety, acute safety events in PROTECT AF were an initial concern. Primary safety events at 18 months occurred at a higher rate in the WATCHMAN group compared to the warfarin group (RR 1.69, 95% CrI 1.01–3.19). The majority of safety events in the WATCHMAN group (55%, 27 out of 49) occurred on the day of the procedure. This contrasts to the warfarin group, which had half (8 out of 16) occur between day 45 and 1 year. The most frequent primary complications were directly procedure related including serious pericardial effusion and procedure-related ischemic stroke. No peri-procedural death or long-term disability occurred within this or in any WATCHMAN clinical trial. In further analysis, there was a significant decline in procedure related safety events within 7 days of the procedure between the first and second halves of the PROTECT AF trial and the Continued Access Protocol Registry (CAP).
This suggested a significant improvement in safety with operator experience and technical refinement of the procedure.

The Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) trial was the second randomized, controlled trial conducted to further evaluate safety and efficacy with the WATCHMAN device in response to U.S. Food and Drug Administration concerns over selection criteria and acute safety events [47]. The PREVAIL trial randomized patients 18 years old or older with nonvalvular AF with a CHADS2 score greater than or equal to 2 or 1 with an additional high-risk characteristic (female age ≥ 75 years, baseline ejection fraction ≥ 30 but < 35%, age 65 to 74 years and either diabetes or coronary disease, and age ≥ 65 years old with congestive heart failure). This was meant to include higher risk patients than were evaluated in PROTECT AF. A total of 407 patients were randomized in a 2:1 fashion with 269 patients in the WATCHMAN group and 138 patients in the warfarin group. The WATCHMAN device was successfully implanted in 95.1% of patients in whom implant was attempted, an improvement from PROTECT AF (p = 0.04). Furthermore, 39.1% of implants were performed by new implanters with no statistically significant difference in success or in complications compared to experienced implanters demonstrating improvements in physician education and the evolution of the procedure. All 7-day complications after attempted implantation including pericardial effusion requiring surgery, pericardial effusion requiring pericardiocentesis, procedure-related strokes, and device embolization occurred at significantly lower rate in PREVAIL compared to PROTECT AF (4.5% versus 8.7%, p = 0.004).

While PROTECT AF, CAP, and PREVAIL included warfarin eligible patients, the group in most need of alternatives to anticoagulation include those nonvalvular AF patients who are unable to be treated with anticoagulation. While there are no randomized trial data, the ASA Plavix Registry (ASAP) study evaluated such patients [48]. A total of 150 nonvalvular AF patients who were ineligible for warfarin were prospectively enrolled in this observational study. Prior bleeding was the main reason for inability to be treated with warfarin. Patients were placed on with clopidogrel for 6 months after implantation of the WATCHMAN device and with aspirin indefinitely thereafter. Patients were followed up for a mean of 14.4±8.6 months. The observed event rate for stroke or systemic embolism was 2.3% per year. The expected event rate based on 1.75. The rate of stroke after 7 days after randomization was 0.0253 in the WATCHMAN arm and 0.0273 in the warfarin arm meeting prespecified criteria for noninferiority. Importantly, the warfarin arm ischemic stroke rate per patient years in PREVAIL (0.70) was significantly lower than all other recent AF studies involving NOACs [i.e. RE-LY (1.7) [13], ARISTOTLE (1.6) [14], and ROCKET AF (2.2) [15]].

While PROTECT AF, CAP, and PREVAIL included warfarin eligible patients, the group in most need of alternatives to anticoagulation include those nonvalvular AF patients who are unable to be treated with anticoagulation. While there are no randomized trial data, the ASA Plavix Registry (ASAP) study evaluated such patients [48]. A total of 150 nonvalvular AF patients who were ineligible for warfarin were prospectively enrolled in this observational study. Prior bleeding was the main reason for inability to be treated with warfarin. Patients were placed on with clopidogrel for 6 months after implantation of the WATCHMAN device and with aspirin indefinitely thereafter. Patients were followed up for a mean of 14.4±8.6 months. The observed event rate for stroke or systemic embolism was 2.3% per year. The expected event rate based on
on a mean CHADS\textsubscript{2} score of 2.8 was 7.3\% per year. This demonstrated an association with significant event rate reduction. Of note, laminar thrombus formation has been reported with the WATCHMAN device. The ASAP trial had six cases of thrombus formation (4\%) on the device with only one resultant clinical event (ischemic stroke). This was similar to PROTECT AF, which had a 4.2\% (20 of 473) thrombus formation rate with three having ischemic strokes. The thrombus-associated annualized stroke rate was 0.3\%. While ASAP was a prospective, observational trial, the totality of data involving the WATCHMAN device remains critical to establishing the LAA as focal source of thromboembolus and that closure of the LAA decreases stroke rate. Data from various studies support WATCHMAN as an alternative to anticoagulation in both warfarin eligible and warfarin ineligible patients.

**Lariat**

The Lariat device (SentreHeart, Redwood City, California, USA) is a transcatheter LAA ligation system that utilizes both endocardial and epicardial approach to place a preformed surgical knot around the ostium of the LAA and approximate all walls thus excluding the LAA [49]. Epicardial access (“dry tap”) is performed through a subxyphoid approach with a micropuncture needle or 17-gauge epidural needle. Access is obtained in the anterior aspect of the pericardial sac with angulation toward the LAA. Dilation up to a 14 French sheath is required. The 14 French epicardial sheath is placed over a stiff guidewire. Femoral venous access is obtained and a transseptal puncture is performed to gain left atrial access. A magnet tip wire is then placed in the LAA endocardially. An epicardial magnet wire is advanced into the pericardial space toward the LAA until a connection is made between the endo- and epi-magnet wires. The Lariat loop snare is then carefully advanced over the epicardial wire while holding the wires in place until the device is placed over the LAA and closed (Figure 5). TEE guidance is utilized to visualize LAA closure and assess adequacy of closure. A preformed surgical knot is deployed. A tensioner is used to tighten the knot before cutting the suture. The procedure is limited to patients with LAA less than 40 mm due to loop snare size. Unfavorable orientation of the appendage determined on the required preoperative CT may exclude the patient from this procedure. It is also limited to patients who have not had previous cardiac surgery. The device currently has FDA 510k approval for tissue approximation. While initial data has demonstrated a high rate of success in terms of closure and leaks, most studies have been small, observational studies. Bartus et al. [49] prospectively enrolled 92 patients who were not warfarin eligible or were poor candidates for warfarin. Presence of pericardial adhesions excluded three patients. The remaining 89 patients underwent attempted Lariat closure of the LAA. Successful closure (< 1 mm residual leak) was performed in 96\% of the patients. Of patients undergoing TEE at one year, 98\% (64 of 65) had complete closure. Complications occurred in five patients with three having pericardial effusions and two having pericarditis. An additional patient developed a late effusion, 2 weeks after LAA closure. More recently, Price et al. [50] retrospectively evaluated the results of Lariat procedures in 154 patients at eight different centers. While procedural success was high (86\%), major complications occurred in 15 patients (9.7\%). Significant pericardial effusion occurred in 16 patients (10.4\%). There were 14 (9.1\%) major bleeds with 4.5\% of all patients needing transfusion. Death, myocardial infarction, or stroke occurred in 4 patients (2.9\%). Thrombus formation at the endocardial site of LAA closure has also been reported [51, 52]. Given the limited data, a large, randomized, controlled trial is needed not only to confirm the apparent high procedural success but also better understand the clinical efficacy of the procedure as well as the procedural risks involved with this technique.

**Wavecrest**

The Wavecrest LAA occluder device (Coherex Medical, Salt Lake City, Utah, USA) is an umbrella shaped device designed to cover the LAA at the ostium. It is constructed with a nitinol frame and covering material with anchoring barbs which are deployed after the covering face is first positioned into place at the osmium (Figure 6). The covering material consists of nonpermeable, Teflon material at the face and a foam
cuff around the face for direct contact with the endocardium. The device is delivered through the femoral vein into the left atrium via trans-septal access and requires fluoroscopy and TEE guidance as with other LAA occluder devices. The Wavecrest device differs from others in that the occluding atraumatic face of the device is deployed first into the LAA at the ostium and advanced outside of the delivery sheath without requiring delivery sheath placement into the LAA itself. Once in position, the deployment anchors are advanced into the LAA body. Currently, dual antiplatelet therapy is recommended after implantation. This device has received CE mark approval. There is limited data concerning clinical outcomes with this device at this time.

Figure 5. Panel A. LARIAT image courtesy of SentreHeart, Inc. Panel B. This left anterior oblique projection demonstrates epicardial and endocardial magnet wires connected at the tip of the left atrial appendage (LAA). An additional wire for maintained pericardial access is also seen. Panel C. This right anterior oblique fluoroscopy image demonstrates the LARIAT snare being placed over the appendage while the endocardial and epicardial magnet wires function as a rail. Once over the base of the LAA, the snare will be closed.
Cardiology/Heart Rhythm Society guidelines for the management of patients with atrial fibrillation discuss percutaneous LAA closure but do not provide any recommendations with regard to its use [54]. Though WATCHMAN has demonstrated noninferiority and superiority compared to warfarin eligible patients, no direct comparison to NOACs is currently available. Indirect comparisons of relative reduction in mortality between NOACs and WATCHMAN compared to warfarin favor LAA closure with WATCHMAN (Figure 7). Indirect comparisons with regard to stroke rate or rate of systemic embolism also appear similar (Figure 8). The debate continues whether the WATCHMAN device should be used as alternative to anticoagulation as in PROTECT AF, CAP and PREVAIL trials or indicated only for those patients with relative or absolute contraindications to anticoagulation as in ASAP. There is a paucity of data with other devices with no other randomized trial data to support LAA closure as an alternative to anticoagulation with such devices at this time. Such devices should be limited to patients with contraindications to anticoagulation until further data are available.

The patients who stand to benefit most from LAA closure include those at highest risk for bleeding. Interestingly, these patients are also at the highest risk of thromboembolic stroke. Continued understanding of risks of transcatheter LAA closure techniques is needed to allow for more accurate risk assessment for patients facing the choice of being at high risk for bleeding com-

Figure 6. WAVECREST. The Wavecrest is an umbrella shaped device constructed with a nitinol frame and covering material with anchoring barbs which are deployed after the covering face is first positioned into place at the ostium. The covering material consists of non-permeable, Teflon material at the face, and a foam cuff around the face for direct contact with the endocardium (image courtesy of Coherex Medical, Inc.).

Discussion

Percutaneous transcatheter LAA closure provides an alternative in the treatment of patients with non-valvular AF at high risk for stroke. Warfarin alone has been the mainstay of therapy until recently with the introduction of NOAC agents. While these agents provide some advantages over warfarin, they are not without risk of bleeding. While risk of intracranial bleeding is less with these agents, overall risk of bleeding is similar to warfarin with the exception of apixaban. Gastrointestinal bleeding is higher with both dabigatran and rivaroxaban compared with warfarin [13, 15]. Currently, there are no approved antidotes for these agents presenting challenges for management. These agents also do not fully address the issue of noncompliance and intolerance with significant discontinuation rates of all oral anticoagulants. Currently, the European Society of Cardiology guidelines for the management of atrial fibrillation support consideration of transcatheter closure of the LAA in patients with a high stroke risk and contraindications for long-term oral anticoagulation [53].
thromboembolism. The individual techniques and devices involved require continued prospective study to demonstrate each device’s efficacy and safety as well as to determine specific anticoagulation or antiplatelet regimens that may or may not be necessary. While data from the only randomized, controlled, trials available compared LAA closure to anticoagulation eligible patients, it is likely that this technology will be limited until further confirmatory data are available. It is clear that a large percentage of patients are currently unable to be treated with oral anticoagulation of any kind. Another option is needed for patients. Further study may expand the indications as technologies continue to develop and more data are available.

Conflict of Interest

Sánchez reports having received consulting fees from Boston Scientific, the manufacturer of the Watchman device. Dr. Holmes has received research grant support from Atritech/Boston Scientific. In addition, the Watchman LAA closure technology has been licensed to Atritech, and both Mayo Clinic and David Holmes have contractual rights to receive future royalties from this license. To date, no royalties have been received.

Figure 8. Indirect comparison of total mortality reduction from major trials. RE-LY [13], ARISTOTLE [14], ROCKET-AF [15], and PROTECT AF [45] trials demonstrating relative risk reduction in total mortality.

Table 2: HAS-BLED

<table>
<thead>
<tr>
<th>HAS-BLED</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension (systolic blood pressure &gt; 160 mm Hg)</td>
<td>1</td>
</tr>
<tr>
<td>Abnormal renal and liver function (1 point each)</td>
<td>1 or 2</td>
</tr>
<tr>
<td>Stroke</td>
<td>1</td>
</tr>
<tr>
<td>Bleeding tendency/predisposition</td>
<td>1</td>
</tr>
<tr>
<td>Labile INRs (if on warfarin)</td>
<td>1</td>
</tr>
<tr>
<td>Elderly (age &gt; 65 years)</td>
<td>1</td>
</tr>
<tr>
<td>Drugs or alcohol (1 point each)</td>
<td>1 or 2</td>
</tr>
<tr>
<td>Maximum score</td>
<td>9</td>
</tr>
</tbody>
</table>

Conclusion

LAA closure is a rapidly developing area of cardiology with significant promise. Transcatheter LAA occlusion has shown that local therapy can reduce systemic complications, at high risk for thromboembolic stroke, or at risk of complications from a percutaneous procedure. Tools such as CHA2DS2-VASc score allow for such determination of CVA risk in nonvalvular AF patients. Assessment of bleeding risk is equally important. The HAS-BLED score [55] has been validated and can be used to determine risk of bleeding among patients who have an indication for anticoagulation (Table 2). The risk of each individual transcatheter technique must be established to accurately determine at what point LAA closure is indicated and the risks acceptable. Consideration of both procedure risks and long-term risks of the device themselves must be evaluated. It is important to note that bleeding and stroke risk continue yearly with life-long anticoagulation, while procedural risks of device implantation are usually short term and should be weighed as such. None the less, there is a large population of patients at this time in need of alternatives especially those with relative and absolute contraindications to anticoagulation use who are also at high risk of thromboembolic stroke from AF.
References


21. Lip G, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors, stroke risk stratification scheme, and prognosis. Stroke. 2007;38:1227-1237. DOI: 10.1161/01.STR.0000260909.90508.3e


41. AMPLATZER cardiac plug clinical trial. Available at: clinicaltrials.gov/ct2/show/record/NCT01118299?term=LAAMCPlugged&rank=3


51. Giedrimas E, Lin AC, Knight BP. Left atrial thrombus after appendage closure using LARIAT. Circ Arrhythm Electrophysiol. 2013;6:e52-e53. DOI: 10.1161/CIR- CEP.113.005532


